Jian Xie Sells 689 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.26, for a total transaction of $12,581.14. Following the completion of the transaction, the chief operating officer now directly owns 336,136 shares in the company, valued at $6,137,843.36. The trade was a 0.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Fulgent Genetics Stock Up 1.0 %

Fulgent Genetics stock opened at $18.07 on Friday. The stock’s fifty day simple moving average is $19.86 and its 200-day simple moving average is $21.14. Fulgent Genetics, Inc. has a twelve month low of $16.56 and a twelve month high of $30.68.

Wall Street Analyst Weigh In

FLGT has been the subject of several research reports. Piper Sandler dropped their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, November 11th. StockNews.com downgraded Fulgent Genetics from a “hold” rating to a “sell” rating in a report on Wednesday.

Institutional Trading of Fulgent Genetics

A number of large investors have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in shares of Fulgent Genetics during the third quarter worth $5,854,000. Millennium Management LLC boosted its position in shares of Fulgent Genetics by 34.3% during the 2nd quarter. Millennium Management LLC now owns 958,852 shares of the company’s stock worth $18,813,000 after acquiring an additional 244,981 shares in the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of Fulgent Genetics by 46.4% in the 2nd quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock valued at $9,912,000 after acquiring an additional 160,212 shares during the last quarter. Invenomic Capital Management LP lifted its stake in Fulgent Genetics by 98.9% during the third quarter. Invenomic Capital Management LP now owns 249,747 shares of the company’s stock worth $5,427,000 after purchasing an additional 124,185 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Fulgent Genetics by 37.6% in the second quarter. Bank of New York Mellon Corp now owns 201,201 shares of the company’s stock valued at $3,948,000 after purchasing an additional 55,020 shares in the last quarter. 48.06% of the stock is currently owned by hedge funds and other institutional investors.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.